Amylin Obesity Pipeline: CagriSema, Amycretin, and the Satiety Layer
The amylin lane matters because it offers a different satiety logic from pure GLP-1. The real question is whether that difference becomes clinically and commercially meaningful enough to reshape the category.
Why this matters
This lane matters because amylin is one of the few mechanisms that can plausibly widen the obesity story without just copying the first GLP-1 wave.
Current read
CagriSema is the near-term commercial event. Amycretin is the longer-range strategic bet. Petrelintide, cagrilintide, and AZD6234 matter because they determine whether amylin becomes a category in its own right or just a helpful add-on.
Primary query
amylin obesity pipeline
Page type
Mechanism Tracker
Lead read
CagriSema
Stage mix
3 phase 2 · 1 filed / decision-stage · 1 phase 3 · 1 phase 1
Pipeline facts for search and AI answers
What this mechanism tracker page answers
Primary query
amylin obesity pipeline
The page is built to answer this pipeline query directly before routing readers deeper.
Tracker type
Mechanism Tracker
This page tracks one mechanism lane and the compounds that currently matter most inside it.
Lead read
CagriSema
CagriSema is the near-term commercial event. Amycretin is the longer-range strategic bet. Petrelintide, cagrilintide, and AZD6234 matter because they determine whether amylin becomes a category in its own right or just a helpful add-on.
Stage mix
3 phase 2 · 1 filed / decision-stage · 1 phase 3 · 1 phase 1
FormBlends separates early pipeline interest from late-stage, filed, and approved assets.
Direct answer
What is it?
CagriSema is a fda-filed program from Novo Nordisk built around GLP-1 + Amylin/Calcitonin.
Why does it matter?
The amylin lane matters because it offers a different satiety logic from pure GLP-1. The real question is whether that difference becomes clinically and commercially meaningful enough to reshape the category.
What should you read next?
What we know right now
The amylin lane matters because it offers a different satiety logic from pure GLP-1. The real question is whether that difference becomes clinically and commercially meaningful enough to reshape the category.
CagriSema is the near-term commercial event. Amycretin is the longer-range strategic bet. Petrelintide, cagrilintide, and AZD6234 matter because they determine whether amylin becomes a category in its own right or just a helpful add-on.
Right now this page is anchored by CagriSema, Amycretin (Zenagamtide), Petrelintide, which is why the lane feels more concrete than a generic trend piece.
What is still uncertain
This topic already includes assets at approval or filing stage, so some of the commercial read is grounded in real regulatory progress rather than pure projection.
The next milestone is regulatory clarity. Once that lands, the conversation shifts quickly toward pricing, rollout, and access.
The biggest mistake in obesity pipeline content is treating strategic interest like commercial inevitability. This page is built to keep those two things separate.
What FormBlends is watching
- Whether CagriSema proves amylin can matter commercially right away
- Whether amycretin earns a more durable strategic role than a single combo launch
- How stand-alone amylin assets differentiate from combination-led stories
Decision path
How should I interpret Amylin Obesity Pipeline: CagriSema, Amycretin, and the Satiety Layer?
This pipeline page is a decision aid for market context, not a patient access page. Use it to understand which mechanisms, companies, and trial stages are worth watching before comparing anything to available care.
- Topic
- amylin obesity pipeline
- Type
- Mechanism Tracker
- Tracked names
- 6
- Stage mix
- 3 phase 2 · 1 filed / decision-stage · 1 phase 3 · 1 phase 1
Step 1
Check maturity
This topic already includes assets at approval or filing stage, so some of the commercial read is grounded in real regulatory progress rather than pure projection.
Step 2
Watch the next signal
The next milestone is regulatory clarity. Once that lands, the conversation shifts quickly toward pricing, rollout, and access.
Open status hubStep 3
Compare to care today
Pipeline excitement should be separated from treatment decisions that require provider review, a legally available medication, and follow-up.
View current optionsHow this lane stacks up right now
A quick read on the compounds carrying the most weight on this page.
| Compound | Developer | Mechanism | Stage | Next step |
|---|---|---|---|---|
| CagriSema | Novo Nordisk | GLP-1 + Amylin/Calcitonin | FDA-filed | Read status page |
| Amycretin (Zenagamtide) | Novo Nordisk | GLP-1/Amylin | Phase 3 | Read status page |
| Petrelintide | Roche/Zealand | Amylin | Phase 2 | Read status page |
| Cagrilintide | Novo Nordisk | Amylin/Calcitonin | Phase 2 | Read status page |
| AZD6234 | AstraZeneca | Selective Amylin Agonist | Phase 2b | Read status page |
| NNC0174-0833 | Novo Nordisk | Amylin | Phase 1 | Read status page |
Featured compounds in this lane
These are the names currently doing the real work in this part of the pipeline.
Related comparisons
Amycretin vs CagriSema: Novo Nordisk's Two Big Combination Bets
CagriSema is the nearer market event. Amycretin is the more strategic long-range bet on where Novo wants combination therapy to go next. If the question is what matters first, CagriSema wins. If the question is what might matter more later, Amycretin is the more interesting asset.
Cagrilintide vs Petrelintide: Which Amylin Pathway Asset Looks Cleaner?
Cagrilintide has the stronger ecosystem. Petrelintide may have the cleaner identity. If you think the amylin pathway wins mainly through big-company combos, cagrilintide matters more. If you think the market may reward a more distinct amylin story, petrelintide is the better watch.
AZD6234 vs Petrelintide: Selective Amylin Agonist vs Roche/Zealand's Amylin Bet
AZD6234 is the more selective mechanism bet. Petrelintide is the more sponsored and visible pathway bet. If the market ends up rewarding cleaner pharmacology, AZD6234 gets more interesting. If it rewards sponsor power and execution, petrelintide has the edge.
FormBlends separates trial-stage tracking from actual patient availability.
Late-stage, filed, and approved assets are treated differently from early exploratory programs.
This page is meant to answer the query fast, then route readers into compound, status, and comparison pages for deeper analysis.